Intranasal administration of Schistosoma japonicum paramyosin induced robust long-lasting systemic and local antibody as well as delayed-type hypersensitivity responses, but failed to confer protection in a mouse infection model

Japanese Journal of Infectious Diseases

Volumn 63, Issue 3, 2010, Pages 166-172

  Kohama, Hideyasu ^a   Harakuni, Tetsuya ^a   Kikuchi, Mihoko ^b   Nara, Takeshi ^c   Takemura, Yasunori ^a   Miyata, Takeshi ^a   Sato, Yoshiya ^a   Hirayama, Kenji ^b   Arakawa, Takeshi ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PARAMYOSIN; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHELMINTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CERCARIA (TREMATODE LARVA); CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; ESCHERICHIA COLI; FEMALE; FERTILITY; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; TH1 CELL; TH2 CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, HELMINTH; CHOLERA TOXIN; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; FREUND'S ADJUVANT; HYPERSENSITIVITY, DELAYED; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SCHISTOSOMA JAPONICUM; SCHISTOSOMIASIS JAPONICA; TROPOMYOSIN;

EID: 77953350134     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. World Health Organization (2007): Shistosomiasis. Fact sheet N°115.
2. Chitsulo, L., Engels, D., Montresor, A., et al. (2000): The global status of schistosomiasis and its control. Acta Trop., 77, 41-51.
3. Ross, A.G., Bartley, P.B., Sleigh, A.C., et al. (2002): Schistosomiasis. N. Engl. J. Med., 346, 1212-1220.
4. Gray, D.J., Williams, G.M., Li, Y., et al. (2008): Transmission dynamics of Schistosoma japonicum in the lakes and marshlands of China. PLoS One, 3, e4058.
5. McManus, D.P. (2005): Prospects for development of a transmission blocking vaccine against Schistosoma japonicum. Parasite Immunol., 27, 297-308.
6. Gray, D.J., Williams, G.M., Li, Y., et al. (2009): A cluster-randomised intervention trial against Schistosoma japonicum in the People's Republic of China: bovine and human transmission. PLoS One, 4, e5900.
7. McManus, D.P. and Bartley, P.B. (2004): A vaccine against Asi-an schistosomiasis. Parasitol. Int., 53, 163-173.
8. McManus, D.P. and Loukas, A. (2008): Current status of vaccines for schistosomiasis. Clin. Microbiol. Rev., 21, 225-242.
9. Bergquist, N.R., Leonardo, L.R. and Mitchell, G.F. (2005): Vaccine-linked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol., 21, 112-117.
10. Fenwick, A., Savioli, L., Engels, D., et al. (2003): Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol., 19, 509-515.
11. Shi, Y.E., Jiang, C.F., Han, J.J., et al. (1990): Schistosoma japonicum: an ultraviolet-attenuated cercarial vaccine applicable in the field for water buffaloes. Exp. Parasitol., 71, 100-106.
12. McManus, D.P. (1999): The search for a vaccine against schistosomiasis-a difficult path but an achievable goal. Immunol. Rev., 171, 149-161.
13. Hernandez, M.G., Hafalla, J.C., Acosta, L.P., et al. (1999): Paramyosin is a major target of the human IgA response against Schistosoma japonicum. Parasite Immunol., 21, 641-647.
14. Kurtis, J.D., Friedman, J.F., Leenstra, T., et al. (2006): Pubertal development predicts resistance to infection and reinfection with Schistosoma japonicum. Clin. Infect. Dis., 42, 1692-1698.
15. Wang, T., Zhang, S., Wu, W., et al. (2006): Treatment and reinfection of water buffaloes and cattle infected with Schistosoma japonicum in Yangtze River Valley, Anhui province, China. J. Parasitol., 92, 1088-1091.
16. Correa-Oliveira, R., Caldas, I.R., and Gazzinelli, G. (2000): Natural versus drug-induced resistance in Schistosoma mansoni infection. Parasitol Today, 16, 397-399.
17. McManus, D.P., Wong, J.Y., Zhou, J., et al. (2002): Recom-binant paramyosin (rec-Sj-97) tested for immunogenicity and vaccine efficacy against Schistosoma japonicum in mice and water buffaloes. Vaccine, 20, 870-878.
18. Chen, H., Nara, T., Zeng, X., et al. (2000): Vaccination of domestic pig with recombinant paramyosin: against Schistosoma japonicum in China. Vaccine, 18, 2142-2146.
19. Jiz, M., Wu, H. W., Meng, R., et al. (2008): Pilot-scale production and characterization of paramyosin, a vaccine candidate for schistosomiasis japonica. Infect. Immun., 76, 3164-3169.
20. Kalinna, B.H., Becker, M.M. and McManus, D.P. (1997): Engineering and expression of a full length cDNA encoding Schistosoma japonicum paramyosin. Purification of the recombinant protein and its recognition by infected patient sera. Acta Trop., 65, 111-115.
21. Jiz, M., Friedman, J.F., Leenstra, T., et al. (2009): Immuno-globulin E (IgE) responses to paramyosin predict resistance to reinfection with Schistosoma japonicum and are attenuated by IgG4. Infect. Immun., 77, 2051-2058.
22. Kojima, S., Niimura, M. and Kanazawa, T. (1987): Production and properties of a mouse monoclonal IgE antibody to Schistosoma japonicum. J. Immunol., 139, 2044-2049.
23. Kojima, S. (2004): Overview: from the horse experimentation by Prof. Akira Fujinami to paramyosin. Parasitol. Int., 53, 151-162.
24. Nara, T., Matsumoto, N., Janecharut, T., et al. (1994): Demonstration of the target molecule of a protective IgE antibody in secretory glands of Schistosoma japonicum larvae. Int. Immunol., 6, 963-971.
25. Matsumoto, Y., Perry, G., Levine, R.J., et al. (1988): Paramyosin and actin in schistosomal teguments. Nature, 333, 76-78.
26. Gobert, G.N., Stenzel, D.J., Jones, M.K., et al. (1997): Schistosoma japonicum: immunolocalization of paramyosin during development. Parasitology, 114 (Pt 1), 45-52.
27. Yang, W., Waine, G.J. and McManus, D.P. (1995): Antibodies to Schistosoma japonicum (Asian bloodfluke) paramyosin induced by nucleic acid vaccination. Biochem. Biophys. Res. Com-mun.,212, 1029-1039.
28. Arakawa, T., Tsuboi, T., Kishimoto, A., et al. (2003): Serum antibodies induced by intranasal immunization of mice with Plas-modium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes. Vaccine, 21, 3143-3148.
29. Arakawa, T., Komesu, A., Otsuki, H., et al. (2005): Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect. Immun., 73, 7375-7380.
30. Arakawa, T., Tachibana, M., Miyata, T., et al. (2009): Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection. Infect. Immun., 77, 5496-5500.
31. Marinaro, M., Staats, H.F., Hiroi, T., et al. (1995): Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol., 155, 4621-4629.
32. Smithers, S.R. (1960): The isolation of viable schistosome eggs by a digestion technique. Trans. R. Soc. Trop. Med. Hyg., 54, 68-70.
33. Comoy, E.E., Capron, A. and Thyphronitis, G. (1998): Adjuvant is the major parameter influencing the isotype profiles generated during immunization with a protein antigen, the Schistosoma mansoni Sm28-GST. Scand. J. Immunol., 47, 444-452.
34. Pearce, E.J., James, S.L., Hieny, S., et al. (1988): Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen. Proc. Natl. Acad. Sci. USA, 85, 5678-5682.
35. Nara, T., Tanabe, K., Mahakunkijcharoen, Y., et al. (1997): The B cell epitope of paramyosin recognized by a protective monoclonal IgE antibody to Schistosoma japonicum. Vaccine, 15, 79-84.
36. Lebens, M., Sun, J.B., Sadeghi, H., et al. (2003): A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection. Vaccine, 21, 514-520.
37. Sun, J.B., Mielcarek, N., Lakew, M., et al. (1999): Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and an-tipathological immunity in mice. J. Immunol., 163, 1045-1052.
38. Yang, W., Gobert, G.N. and McManus, D.P. (1997): Oral vaccination of mice with recombinant Schistosoma japonicum proteins induces specific anti-parasite antibodies and damage to adult worms after a challenge infection. Int. J. Parasitol., 27, 843-853.
39. Li, Y., Sleigh, A.C., Ross, A.G., et al. (2001): Human susceptibility to Schistosoma japonicum in China correlates with antibody isotypes to native antigens. Trans. R. Soc. Trop. Med. Hyg., 95, 441-448.
40. Strait, T.R., Morris, C.S. and Finkelman, D.F. (2006): IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcgRIIb cross-linking. J. Clin. Invest., 116, 833-841.
41. Garcia B.E., Sanz, M.L., Gato, J.J., et al. (1993): IgG4 blocking effect on the release of antigen-specific histamine. J. Investig. Al-lergol. Clin. Immunol., 3, 26-33.